{"id":"W4323294773","doi":"10.2217/fon-2022-1059","title":"TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i> -positive non-small-cell lung cancer and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Brain metastasis; Clinical trial; Interim analysis; Clinical endpoint; Adverse effect; Adenocarcinoma; Metastasis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00190756,0.001283991,0.001061038,0.0003617262,0.0002816904,0.0009979488,0.0007195306,0.0009749143,0.003708976],"category_scores_gemma":[0.0006243581,0.000364994,0.001297851,0.000453278,0.0006322598,0.0007684347,0.0007018399,0.001997572,0.0009598041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001333744,"about_ca_system_score_gemma":0.002014456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001594408,"about_ca_topic_score_gemma":0.005565062,"domain_scores_codex":[0.9995579,0.000176147,0.00002333755,0.00007407743,0.00004883307,0.000119628],"domain_scores_gemma":[0.9996279,0.00002927239,0.00008863646,0.00002929696,0.0000436449,0.0001811588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3288563,0.03914946,0.02469399,0.003985295,0.00305172,0.0008660494,0.0006205571,0.009510906,0.3258755,0.002785264,0.03879668,0.2218083],"study_design_scores_gemma":[0.4451852,0.4012955,0.05013498,0.0003239913,0.002438866,0.002725299,0.0003985374,0.004657617,0.04095297,0.001042301,0.05068171,0.000163124],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9570775,0.005914934,0.004232592,0.001745664,0.0002642787,0.009787624,0.008520666,0.0005159252,0.01194097],"genre_scores_gemma":[0.9553458,0.003925161,0.007119439,0.00232659,0.0001395969,0.00652377,0.01681639,0.0002608933,0.00754235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003708976,"threshold_uncertainty_score":0.01240778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01232102561456113,"score_gpt":0.3856566028457878,"score_spread":0.3733355772312267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}